The cobas® BKV test is a diagnostic tool that aims to provide reliable and standardized results for improved management of transplant patients at risk of infection. It is used to assess if transplant patients are at risk of developing disease caused by BKV, which can contribute to graft loss or organ rejection. This test is intended to be used on the automated cobas® 5800/6800/8800 Systems.

The features and benefits of the cobas® BKV test include standardization of results that are traceable to the WHO International Standard and reporting in IU/mL, which improves harmonization in testing results across hospitals and institutions. The test also has state-of-the-art design with a dual target assay that provides reliable and reproducible results for reassurance in clinical decision making. Additionally, it has efficiency, flexibility and simplicity, with the ability to perform critical transplant testing (CMV, EBV, BKV) from a single sample on the cobas® 5800/6800/8800 Systems with an industry-leading menu, absolute automation and proven performance. The cobas BKV test also enables BKV urine testing the right way, with urine sample stabilized in cobas® PCR media which allows result integrity to be maintained, enabling faster preparation and making storage and transportation more convenient without the need of refrigeration. BK polyomavirus (BKV) could cause transplant-transmitted infections in immunocompromised transplant patients and is linked to post-transplant complications, such as nephropathy in kidney transplants and hemorrhagic cystitis in hematopoietic stem cell transplants. Early intervention with best-in-class monitoring tools provides actionable results which enable informed treatment decisions.

Facebook Page of the Product

Twitter Page of the Product

linkedin Page of the Product

Website of the Product